Why α2-antiplasmin must be converted to a derivative form for optimal function

Journal of Thrombosis and Haemostasis

Volumn 5, Issue 10, 2007, Pages 2095-2104

  Lee, Kyung N ^a   Jackson, K W ^a   Christiansen, V J ^a   Lee, C S ^a   Chun, J G ^a   Mckee, P A ^a  

^a UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

Author keywords

2 antiplasmin; 5 (biotinamido)pentylamine; Antiplasmin cleaving enzyme; Factor XIII; Fibrinolysis; Fibroblast activation protein

Indexed keywords

5 (BIOTINAMIDO)PENTYLAMINE; ALPHA 2 ANTIPLASMIN; ANTIPLASMIN CLEAVING ENZYME; ASPARAGINE; BLOOD CLOTTING FACTOR 13A; FIBRIN; GLUTAMINE; ISOPROTEIN; METHIONINE; PENTYLAMINE; PLASMIN; SERINE PROTEINASE; UNCLASSIFIED DRUG; 5-(BIOTINAMIDO)PENTYLAMINE; AMINE; ANTIPLASMIN; ANTIPLASMIN CLEAVING ENZYME, HUMAN; ANTIPLASMIN-CLEAVING ENZYME, HUMAN; BIOTIN; BLOOD CLOTTING FACTOR 13; CROSS LINKING REAGENT; DRUG DERIVATIVE; FAP PROTEIN, HUMAN; PEPTIDE; TUMOR ANTIGEN; TUMOR MARKER;

AMINO ACID SEQUENCE; AMINO TERMINAL SEQUENCE; ARTICLE; BLOOD CLOT LYSIS; CONTROLLED STUDY; ENZYME ACTIVITY; HUMAN; MOLECULAR INTERACTION; PRIORITY JOURNAL; PROTEIN CROSS LINKING; PROTEIN DEGRADATION; PROTEIN FUNCTION; PROTEIN METABOLISM; PROTEIN STRUCTURE; SEQUENCE ANALYSIS; SINGLE NUCLEOTIDE POLYMORPHISM; AFFINITY CHROMATOGRAPHY; BIOLOGICAL MODEL; CHEMISTRY; FIBRINOLYSIS; GENETIC POLYMORPHISM; LIVER; METABOLISM; PROTEIN TERTIARY STRUCTURE;

AMINES; ANTIGENS, NEOPLASM; ANTIPLASMIN; BIOTIN; CHROMATOGRAPHY, AFFINITY; CROSS-LINKING REAGENTS; FACTOR XIII; FIBRIN; FIBRINOLYSIS; HUMANS; LIVER; MODELS, BIOLOGICAL; PEPTIDES; POLYMORPHISM, GENETIC; PROTEIN STRUCTURE, TERTIARY; SERINE ENDOPEPTIDASES; TUMOR MARKERS, BIOLOGICAL;

EID: 34548823785     PISSN: 15387933     EISSN: 15387836     Source Type: Journal    
DOI: 10.1111/j.1538-7836.2007.02707.x     Document Type: Article

References (30)

1. Collen D. Identification and some properties of a new fast-reacting plasmin inhibitor in human plasma. Eur J Biochem 1976; 69: 209-16.
2. 2 -plasmin inhibitor from human plasma. A novel proteinase inhibitor which inhibits activator-induced clot lysis. J Biol Chem 1976; 251: 5956-65.
3. Mullertz S, Clemmensen I. The primary inhibitor of plasmin in human plasma. Biochem J 1976; 159: 545-53.
4. 2-plasmin inhibitor in human plasma. Biochem J 1993; 291: 623-5.
5. 2-plasmin inhibitor from human plasma and culture media of Hep G2 cells. Biochem Biophys Res Commun 1994; 200: 417-22.
6. 2-antiplasmin inhibition of fibrin digestion. Blood 2004; 103: 3783-8.
7. Lee KN, Jackson KW, Christiansen VJ, Lee CS, Chun JG, McKee PA. Antiplasmin-cleaving enzyme is a soluble form of fibroblast activation protein. Blood 2006; 107: 1397-404.
8. Park JE, Lenter MC, Zimmermann RN, Garin-Chesa P, Old LJ, Rettig WJ. Fibroblast activation protein, a dual specificity serine protease expressed in reactive human tumor stromal fibroblasts. J Biol Chem 1999; 274: 36505-12.
9. Huang Y, Wang S, Kelly T. Seprase promotes rapid tumor growth and increased microvessel density in a mouse model of human breast cancer. Cancer Res 2004; 64: 2712-6.
10. 2-plasmin inhibitor gene. Proc Natl Acad Sci USA 1988; 85: 6836-40.
11. 2-antiplasmin) gene associated with a bleeding tendency. Br J Haematol 1999; 107: 317-22.
12. 2-antiplasmin activity. Blood 2007; 109: 5286-92.
13. 2-antiplasmins to fibrin by activated factor XIII and by a tissue transglutaminase. J Biol Chem 2000; 275: 37382-9.
14. Wiman B, Collen D. Purification and characterization of human antiplasmin, the fast-acting plasmin inhibitor in plasma. Eur J Biochem 1977; 78: 19-26.
15. Folk JE, Chung SI. Transglutaminases Methods Enzymol 1985; 113: 358-75.
16. Schwartz ML, Pizzo SV, Hill RL, McKee PA. Human factor XIII from plasma and platelets. Molecular weights, subunit structures, proteolytic activation, and cross-linking of fibrinogen and fibrin. J Biol Chem 1973; 248: 1395-407.
17. Jones AJ, Meunier AM. A precise and rapid microtitre plate clot lysis assay: Methodology, kinetic modeling and measurement of catalytic constants for plasminogen activation during fibrinolysis. Thromb Haemost 1990; 64: 455-63.
18. 2-antiplasmin on urokinase-induced fibrinolysis. Thromb Haemost 1998; 80: 637-44.
19. 2-antiplasmins: Fibrinolysis enhancement by reactive site mutant. Blood 1999; 94: 164-71.
20. Lee KN, Maxwell MD, Patterson MK Jr., Birckbichler PJ, Conway E. Identification of transglutaminase substrates in HT29 colon cancer cells: Use of 5-(biotinamido)pentylamine as a transglutaminase-specific probe. Biochim Biophys Acta 1992; 1136: 12-6.
21. 2-Antiplasmin: Potential therapeutic roles in fibrin survival and removal. Curr Med Chem Cardiovasc Hematol Agents 2004; 2: 303-10.
22. 2-plasmin inhibitor to fibrin catalyzed by activated fibrin-stabilizing factor. J Biol Chem 1982; 257: 14767-72.
23. 2 -plasmin inhibitor to fibrin in inhibition of fibrinolysis and in hemostasis. J Clin Invest 1982; 69: 536-42.
24. 2-antiplasmin to fibrin is a key factor in regulating blood clot lysis: Species differences. Blood Coagul Fibrinolysis 1993; 4: 869-75.
25. 2-plasmin inhibitor. J Biochem (Tokyo) 1989; 106: 703-7.
26. 2-plasmin inhibitor. J Biol Chem 1986; 261: 15591-5.
27. Sugimura Y, Hosono M, Wada F, Yoshimura T, Maki M, Hitomi K. Screening for the preferred substrate sequence of transglutaminase using a phage-displayed peptide library: Identification of peptide substrates for TGASE 2 and factor XIIIA. J Biol Chem 2006; 281: 17699-706.
28. Nahrendorf M, Hu K, Frantz S, Jaffer FA, Tung CH, Hiller KH, Voll S, Nordbeck P, Sosnovik D, Gattenlöhner S, Novikov M, Dickneite G, Reed GL, Jakob P, Rosenzweig A, Bauer WR, Weissleder R, Ertl G. Factor XIII deficiency causes cardiac rupture, impairs wound healing, and aggravates cardiac remodeling in mice with myocardial infarction. Circulation 2006; 113: 1196-202
29. Reed GL., Houng AK. The contribution of activated factor XIII to fibrinolytic resistance in experimental pulmonary embolism. Circulation 1999; 99: 299-304.
30. 2-antiplasmin enhances in vivo thrombolysis. Circulation 1990; 82: 164-8.